Volume 32, Issue 2 pp. 334-340
Original Article
Free Access

Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis

Nils Kinnman M.D.

Corresponding Author

Nils Kinnman M.D.

Department of Gastroenterology and Hepatology, Karolinska Hospital, Stockholm

Institut National de la Santé et de la Recherche Médicale U402, Faculté de Médecine Saint-Antoine, Paris, France

INSERM Unité 402, Faculté de Médecine Saint Antoine, 27, rue de Chaligny, 75571 Paris cedex 12, France. fax: (33) 1-40-01-14-99.===Search for more papers by this author
Anders Lindblad

Anders Lindblad

Department of Pediatrics, Göteborg University, Sweden

Search for more papers by this author
Chantal Housset

Chantal Housset

Institut National de la Santé et de la Recherche Médicale U402, Faculté de Médecine Saint-Antoine, Paris, France

Search for more papers by this author
Eva Buentke

Eva Buentke

Department of Clinical Immunology, Karolinska Institutet, Karolinska Hospital, Stockholm

Search for more papers by this author
Annika Scheynius

Annika Scheynius

Department of Clinical Immunology, Karolinska Institutet, Karolinska Hospital, Stockholm

Search for more papers by this author
Birgitta Strandvik

Birgitta Strandvik

Department of Pediatrics, Göteborg University, Sweden

Search for more papers by this author
Rolf Hultcrantz

Rolf Hultcrantz

Department of Gastroenterology and Hepatology, Karolinska Hospital, Stockholm

Search for more papers by this author
First published: 30 December 2003
Citations: 65

Abstract

The authors examined the expression of cystic fibrosis transmembrane conductance regulator (CFTR) and its relationship to histopathological changes in cystic fibrosis (CF) liver tissue. Immunohistochemistry was used to examine expression of CFTR, intercellular adhesion molecule-1 (ICAM-1) and liver cell-type markers in liver cryosections in 11 patients with CF-associated liver disease, and non-CF controls with (n = 17) and without (n = 3) liver disease. In CF patients prominent inflammatory infiltrates were not found, yet hepatic stellate cells were identified within fibrotic areas around bile ducts. Proliferating bile ducts displayed ICAM-1 immunoreactivity in 3 cases, but bile ducts were otherwise negative. In 2 patients homozygous for R764X and for 1112delT no CFTR immunoreactivity was detected. Bile-duct epithelial cells in patients carrying the ΔF508 mutation displayed aberrant cytoplasmic immunolocalization of CFTR, as determined with confocal laser scanning microscopy, in contrast to the distinct CFTR expression at the luminal surface seen in controls. No clear relationship between CFTR expression and fibrosis or inflammation was evidenced in CF patients. In conclusion, these findings are consistent with an impairment of ΔF508 CFTR processing in intrahepatic biliary epithelium. ICAM-1 expression on bile-duct epithelial cells and inflammatory infiltrates were rare findings in CF liver tissue, indicating that immunological mechanisms are unlikely to be involved in initiation of CF-associated liver disease.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.